Beam Therapeutics (BEAM) Wells Fargo 21st Annual Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Wells Fargo 21st Annual Healthcare Conference summary
8 Sep, 2026Technology and platform overview
Base editing enables precise, single-letter genetic corrections without double-stranded breaks, offering predictable and uniform genome modifications for various diseases.
Applications include ex vivo and in vivo therapies for sickle cell disease, alpha-1 antitrypsin deficiency, PKU, GSD1A, and other metabolic disorders, aiming for one-time functional cures.
Recent clinical data and efficacy
New data show patients with alpha-1 antitrypsin deficiency reach protective protein levels (≥11 micromolar), with durable effects over 18+ months and over 80% reduction in toxic Z protein.
Functional assays confirm the produced protein is fully functional, with over 90% M form and under 10% Z form, and reductions in harmful Z-AAT polymers and neutrophil elastase.
Efficacy in liver disease patients mirrors lung patients, with tripled alpha-1 levels and mostly mild, transient safety findings.
Safety and patient experience
Safety profile remains favorable, with most liver enzyme elevations being mild and transient; one Grade 3 event resolved without intervention.
Patients show strong interest in one-and-done therapies, citing burdensome current treatments and the appeal of durable, inducible correction.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update